Results 281 to 290 of about 244,635 (318)

Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Polatuzumab vedotin (Pola) is an antibody‐drug conjugate approved for the treatment of diffuse large B‐cell lymphoma (DLBCL). Several reports suggest that the tumor microenvironment influences the outcome of DLBCL treatments; with Pola, however, the link between tumor microenvironment and treatment outcome remains unclear ...
Mayu Tomita, Natsumi Kawasaki, Keigo Yorozu, Sei Shu, Chie Kato, Mitsue Kurasawa, Bansho Masutani, Nicolas Sax, Yoriko Yamashita‐Kashima, Shigeki Yoshiura   +9 more
wiley   +1 more source

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial. [PDF]

Cancers (Basel)
Joffe E, Kumar A, Tuscano JM, Moskowitz AJ, Owens C, Noy A, Palomba ML, Zelenetz AD, Ni A, Sharon E, Vardhana S.   +10 more
europepmc   +1 more source

Myeloid sarcoma masquerading as central nervous system diffuse large b-cell lymphoma: a case report and literature review. [PDF]

Front Oncol
Hu W, Liu Y, Ma C, Gao Y, Zeng P, Chen H.   +5 more
europepmc   +1 more source

Clinical characteristics and long-term prognosis of primary mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma in the small intestine. [PDF]

Transl Cancer Res
Ding J, Liu L, Ye Y.
europepmc   +1 more source

Emergency Management of Diffuse Large B-cell Lymphoma: A Case of Superior Vena Cava Syndrome and Chylothorax. [PDF]

Cureus
Araújo SG, Araújo IM, Robalo M, Esperança S, Oliveira A.   +4 more
europepmc   +1 more source

Robust Multimodal Deep Learning for Lymphoma Subtype Classification Using ¹⁸F-FDG PET Maximum Intensity Projection Images and Clinical Data: A Multi-Center Study. [PDF]

Cancers (Basel)
Kim S, Park JH, Kim CH, You S, Choi JS, Chang JW, Jo IY, Lee BJ, Park IS, Kim HS, Park YJ, Heo J.   +11 more
europepmc   +1 more source